Advanced Filters
noise

Found 706 clinical trials

Mini Theta Burst TMS to Promote Brain Plasticity Indexed by fMRI

Non-invasive transcranial magnetic stimulation (TMS) is now FDA-approved for the treatment of major depressive disorder (MDD). However, there is growing evidence that the targeting strategy for delivering TMS treatment would yield superior clinical outcomes if it were more tailored to individual neuroanatomy. In this study, we plan to examine whether …

99 years and younger
All

MRI Quantification of Hip Bone Microstructure in Stage 4 and 5 Chronic Kidney Disease

University of Pennsylvania Department of Radiology is conducting a research study on hip bone microstructure and strength in people with AND without chronic renal disease. The purpose of this research is to examine the microstructure of bone in the hip using a new, MRI-based approach.

21-50 years
All
Phase N/A

11C-Trimethoprim PET/CT imaging to evaluate biodistribution and kinetics in human subjects

Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will …

18-99 years
All
Phase N/A

The influence of nicotinic hepatic metabolism on neuroreceptor substrates of nicotine addiction

We will examine differences in nAChR availability based on individual differences in the nicotine metabolism rate. Work conducted by Dr. Lermans group at Penn, in collaboration with Drs. Rachel Tyndale (University of Toronto) and Neal Benowitz (University of California, San Francisco) has documented differences in smoking cessation and treatment response …

18-99 years
All
Phase 1

2D AND 4D CONTRAST-ENHANCED ULTRASOUND EVALUATION OF HEPATOCELLULAR CARCINOMA CHEMOEMBOLIZATION

This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced …

99 years and younger
All

Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer

This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …

99 years and younger
All
Phase 1

RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective …

99 years and younger
All
Phase 2

EVALUATION OF THE VALIANT MONA LSA THORACIC STENT GRAFT SYSTEM IN DESCENDING THORACIC AORTIC ANEURYSMS AND CHRONIC DISSECTIONS

The trial involves an investigational device (not approved by the FDA) for subjects who have an aneurysm (bulge), dissection (tear) or a penetrating ulcer (bubble) of the descending aorta that involve an artery (main blood vessel in your body). The subject must need to have one of their blood vessels …

99 years and younger
All

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …

99 years and younger
All
Phase 3

Simplify language using AI